Azithromycin Cuts Pulmonary Exacerbation in CF With Early Pa

Share this content:
Azithromycin Cuts Pulmonary Exacerbation in CF With Early <i>Pa</i>
Azithromycin Cuts Pulmonary Exacerbation in CF With Early Pa

WEDNESDAY, June 27, 2018 (HealthDay News) -- For children with cystic fibrosis (CF) and early Pseudomonas aeruginosa (Pa) infection, the risk of pulmonary exacerbation is significantly reduced with the addition of azithromycin to tobramycin inhalation solution (TIS), according to a study published online June 11 in the American Journal of Respiratory and Critical Care Medicine.

Nicole Mayer-Hamblett, Ph.D., from the University of Washington in Seattle, and colleagues conducted a randomized trial in children ages 6 months to 18 years with CF and early Pa. Children were given azithromycin (110 participants) or placebo (111 participants) three times weekly in addition to standardized TIS.

The trial reached the pre-specified interim boundary for efficacy, and consequently, enrollment was stopped early by the National Heart, Lung, and Blood Institute. The researchers found that compared with placebo, the risk of pulmonary exacerbation was significantly reduced by 44 percent in the azithromycin group. There was a significant 1.27 kg increase in weight in the azithromycin versus the placebo group. There were no significant differences in microbiologic or other clinical or safety end points.

"Azithromycin was associated with a significant reduction in risk of pulmonary exacerbation and sustained improvement in weight but had no impact on microbiologic outcomes in children with early Pa," the authors write.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Access to In-Home Support Soon to Be Available for Seniors

Access to In-Home Support Soon to Be Available ...

Under Medicare Advantage, a health-related reason will be needed to qualify; costs will vary

USPSTF Recommends Screening Adults for Unhealthy Alcohol Use

USPSTF Recommends Screening Adults for Unhealthy Alcohol Use

Recommendation applies to all adults, including pregnant women; insufficient evidence for teens

AHA: Icosapent Ethyl Cuts CV Risk From Elevated Triglycerides

AHA: Icosapent Ethyl Cuts CV Risk From Elevated ...

Ischemic events reduced among patients with elevated triglycerides despite taking statins

is free, fast, and customized just for you!




Already a member?

Sign In Now »